logo
logo
Penumbra, Inc.

Penumbra, Inc.

NYSE•PEN
CEO: Mr. Adam Elsesser J.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2015-09-18
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
連絡先情報
One Penumbra Place, Alameda, CA, 94502, United States
510-748-3200
www.penumbrainc.com
時価総額
$13.30B
PER (TTM)
80.8
38.4
配当利回り
--
52週高値
$362.41
52週安値
$221.26
52週レンジ
83%
順位28Top 16.1%
5.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$354.69M+17.82%
直近4四半期の推移

EPS

$1.17+53.95%
直近4四半期の推移

フリーCF

$42.01M-17.64%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Total revenue reached $1.02B USD for nine months, marking a strong 15.8% increase over prior year period.
Profitability Reversal Strong Swung to $130.3M USD net income for nine months, compared to $19.7M USD net loss last year.
Gross Margin Expansion Gross margin improved 4.9 percentage points to 66.8% for nine months, driven by favorable product mix and productivity.
Operating Cash Flow Stronger Net cash provided by operating activities was $152.2M USD, up $34.8M USD compared to the prior nine months.

リスク要因

Intense Industry Competition Must compete against large, well-capitalized companies requiring continuous successful product introduction and market acceptance.
Foreign Exchange Exposure International sales denominated in local currencies create foreign exchange risk; currently no hedging strategy is in place.
SG&A Expense Rising SG&A increased $56.3M USD (13.2%) for nine months, driven by headcount growth supporting strategic business expansion.
R&D Milestone Timing Future R&D expenses may fluctuate due to timing of clinical trials and product development milestones impacting operating results.

見通し

Share Repurchase Extended Board extended share repurchase authorization by $100.0M USD, available through December 31, 2025, for stock buybacks.
Continued Product Investment Expect continued investment in product development, salesforce expansion, and building inventory ahead of anticipated future sales growth.
Costa Rica Facility Build Ongoing $58M USD capital project in Costa Rica for manufacturing facility construction and warehouse expansion is proceeding.
Effective Tax Rate Volatility Future effective tax rate subject to volatility based on stock price, vesting volume, and changes in tax law interpretation.

同業比較

売上高 (TTM)

Molina Healthcare, Inc.MOH
$45.43B
+11.7%
DaVita Inc.DVA
$13.64B
+6.5%
Henry Schein, Inc.HSIC
$12.94B
+3.5%

粗利益率 (最新四半期)

BioMarin Pharmaceutical Inc.BMRN
81.2%
+7.2pp
Hims & Hers Health, Inc.HIMS
73.8%
-5.4pp
Penumbra, Inc.PEN
67.8%
+1.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ALGN$14.08B34.310.4%1.3%
PEN$13.30B80.813.1%12.4%
ELAN$12.72B353.40.6%29.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.0%
緩やかな成長
4四半期純利益CAGR
10.8%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月17日
|
EPS:$1.12
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $354.69M+17.8%
    |
    EPS: $1.17+53.9%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月29日|
    売上高: $339.46M+13.4%
    |
    EPS: $1.17-175.5%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月23日|
    売上高: $324.14M+16.3%
    |
    EPS: $1.02+264.3%
    予想を上回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月18日|
    売上高: $1.19B+12.9%
    |
    EPS: $0.36-84.8%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月30日|
    売上高: $301.04M+11.1%
    |
    EPS: $0.76+216.7%
    予想を上回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月30日|
    売上高: $299.40M+14.5%
    |
    EPS: $-1.55-416.3%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $278.66M+15.4%
    |
    EPS: $0.28+27.3%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月22日|
    売上高: $1.06B+25.0%
    |
    EPS: $2.37+4580.2%
    予想を上回る